| Literature DB >> 28544703 |
Sho Nishimura1, Eiji Oki1, Koji Ando1, Makoto Iimori2, Yu Nakaji1, Yuichiro Nakashima1, Hiroshi Saeki1, Yoshinao Oda3, Yoshihiko Maehara1.
Abstract
Chromosomal instability (CIN), characterized by aneuploidy, is a major molecular subtype of gastric cancer. The deubiquitinase USP44 is an important regulator of APC activation in the spindle checkpoint and leads to proper chromosome separation to prevent aneuploidy. Aberrant expression of USP44 leads CIN in cells; however, the correlation between USP44 and DNA aneuploidy in gastric cancer is largely unknown. We analyzed USP44 expression in 207 patients with gastric cancer by immunohistochemistry and found that the proportion of USP44 expression was higher in gastric cancer tumors (mean, 39.6%) than in gastric normal mucosa (mean, 14.6%) (P < 0.0001). DNA aneuploidy was observed in 124 gastric cancer cases and high USP44 expression in cancer strongly correlated with DNA aneuploidy (P = 0.0005). The overall survival was significantly poorer in the high USP44 expression group compared with the low USP44 group (P = 0.033). Notably, USP44 expression had no prognostic impact in the diploid subgroup; however, high USP44 expression was a strong poor prognostic factor for progression-free survival (P = 0.018) and overall survival (P = 0.036) in the aneuploid subgroup. We also confirmed that stable overexpression of USP44 induced somatic copy-number aberrations in hTERT-RPE-1 cells (50.6%) in comparison with controls (6.6%) (P < 0.0001). Collectively, our data show USP44 has clinical impact on the induction of DNA aneuploidy and poor prognosis in the CIN gastric cancer subtype.Entities:
Keywords: Chromosome instability; USP44; gastric cancer; prognosis
Mesh:
Substances:
Year: 2017 PMID: 28544703 PMCID: PMC5463085 DOI: 10.1002/cam4.1090
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1Immunohistochemistry of USP44 expression in human gastric cancer clinical samples. Immunohistochemical detection of USP44 in human gastric cancer specimens was performed. Representative low USP44 expression (A) and high USP44 expression cases (B) are shown. (C) Immunohistochemical detection of USP44 in normal mucosa (left) and cancer (right) within the same case. (D) Bar graphs showing the individual proportion of positive nuclei in the normal mucosa (n = 85) and (E) cancer cases (n = 207).
USP44 expression and clinicopathological factors in gastric cancer
| Factors | USP44 expression | ||
|---|---|---|---|
| Low ( | High ( |
| |
| Age (mean ± SD) | 62.8 ± 11.5 | 64.8 ± 12.7 | 0.25 |
| Sex | |||
| Male | 78 (66.7) | 60 (66.7) | 1 |
| Female | 39 (33.3) | 30 (33.3) | |
| Differentiation | |||
| Well/mod | 52 (44.4) | 35 (38.9) | 0.62 |
| Poor/sig | 57 (48.7) | 50 (55.6) | |
| Other | 8 (6.8) | 5 (5.6) | |
| Depth of invasion | |||
| M, SM, MP | 34 (29.1) | 16 (17.8) | 0.06 |
| SS, SE, SI | 83 (70.9) | 74 (82.2) | |
| Lymph node metastasis | |||
| Negative | 38 (32.5) | 27 (30) | 0.55 |
| Positive | 79 (67.5) | 63 (70) | |
| Vascular involvement | |||
| Negative | 69 (59) | 50 (55.6) | 0.62 |
| Positive | 48 (41) | 40 (42.5) | |
| Lymphatic vessel invasion | |||
| Negative | 28 (23.9) | 31 (34.4) | 0.1 |
| Positive | 89 (76.1) | 59 (65.6) | |
| Distant metastasis | |||
| Negative | 94 (80.3) | 66 (73.3) | 0.25 |
| Positive | 23 (19.4) | 24 (26.7) | |
| Stage | |||
| I | 23 (19.7) | 12 (13.3) | 0.44 |
| II | 28 (23.9) | 20 (22.2) | |
| III | 43 (36.8) | 33 (36.7) | |
| IV | 23 (19.7) | 25 (27.8) | |
| DNA ploidy | |||
| Diploidy | 59 (49.6) | 24 (26.7) | 0.0005 |
| Aneuploidy | 58 (50.4) | 66 (73.3) | |
Values in parentheses indicate %.
Well, well differentiated carcinoma; mod, moderately differentiated carcinoma; poor, poorly differentiated carcinoma; sig, signet‐ring cell carcinoma; M, mucosa; SM, submucosa: MP, muscularis propria; SS, subserosa; SE, penetration of serosa; SI, invasion of adjacent structures.
P < 0.001.
Subgroup analysis for USP44 expression and clinicopathological factors
| Factors | USP44 expression | ||
|---|---|---|---|
| Low | High |
| |
| Diploid cases | ( | ( | |
| Age (mean ± SD) | 61.8 ± 13 | 62.8 ± 14.8 | 0.77 |
| Sex | |||
| Male | 42 (71.2) | 14 (58.3) | 0.26 |
| Female | 17 (28.8) | 10 (41.7) | |
| Differentiation | |||
| Well/mod | 22 (37.3) | 8 (33.3) | 0.8 |
| Poor/sig | 32 (54.2) | 15 (62.5) | |
| Other | 5 (8.5) | 1 (4.2) | |
| Depth of invasion | |||
| M, SM, MP | 15 (25.4) | 5 (20.8) | 0.78 |
| SS, SE, SI | 44 (74.6) | 19 (79.2) | |
| Lymph node metastasis | |||
| Negative | 20 (33.9) | 10 (41.7) | 0.5 |
| Positive | 39 (66.1) | 14 (58.3) | |
| Vascular involvement | |||
| Negative | 36 (61) | 16 (66.7) | 0.63 |
| Positive | 23 (39) | 8 (33.3) | |
| Lymphatic vessel invasion | |||
| Negative | 11 (18.6) | 7 (29.2) | 0.29 |
| Positive | 48 (81.4) | 17 (70.8) | |
| Distant metastasis | |||
| Negative | 45 (76.3) | 20 (83.3) | 0.57 |
| Positive | 14 (23.7) | 4 (16.7) | |
| Stage | |||
| I | 10 (17) | 3 (12.5) | 0.83 |
| II | 15 (25.4) | 8 (33.3) | |
| III | 20 (33.9) | 9 (37.5) | |
| IV | 14 (23.7) | 4 (16.7) | |
| Aneuploid cases | ( | ( | |
| Age (mean ± SD) | 64 ± 13 | 65.4 ± 11.9 | 0.48 |
| Sex | |||
| Male | 36 (62.1) | 46 (69.7) | 0.37 |
| Female | 22 (37.9) | 20 (30.3) | |
| Differentiation | |||
| Well/mod | 30 (51.7) | 27 (40.9) | 0.49 |
| Poor/sig | 25 (43.1) | 35 (53) | |
| Other | 3 (5.2) | 4 (6.1) | |
| Depth of invasion | |||
| M, SM, MP | 19 (32.8) | 11 (16.7) | 0.0036 |
| SS, SE, SI | 39 (67.2) | 55 (83.3) | |
| Lymph node metastasis | |||
| Negative | 18 (31) | 17 (25.8) | 0.51 |
| Positive | 40 (69) | 49 (74.2) | |
| Vascular involvement | |||
| Negative | 33 (56.9) | 34 (51.5) | 0.55 |
| Positive | 25 (43.1) | 32 (48.5) | |
| Lymphatic vessel invasion | |||
| Negative | 17 (29.3) | 24 (36.3) | 0.4 |
| Positive | 41 (70.7) | 42 (63.6) | |
| Distant metastasis | |||
| Negative | 49 (84.5) | 46 (69.7) | 0.05 |
| Positive | 9 (15.5) | 20 (30.3) | |
| Stage | |||
| I | 13 (22.4) | 9 (13.6) | 0.16 |
| II | 13 (22.4) | 12 (18.2) | |
| III | 23 (39.7) | 24 (36.4) | |
| IV | 9 (15.5) | 21 (31.8) | |
Values in parentheses indicate %.
Well, well differentiated carcinoma; mod, moderately differentiated carcinoma; poor, poorly differentiated carcinoma; sig, signet‐ring cell carcinoma; M, mucosa; SM, submucosa: MP, muscularis propria; SS, subserosa; SE, penetration of serosa; SI, invasion of adjacent structures.
P < 0.05.
Figure 2Kaplan–Meier curves for gastric cancer cases separated by USP44 expression. (A) Progression‐free survival (PFS) and (B) overall survival (OS) curves for the low USP44 expression group (solid line) and high USP44 expression group (dotted line) (all cases, n = 207). (C) PFS and (D) OS in subgroups according to USP44 expression among diploid cases (n = 83). (E) PFS and (E) OS in subgroups according to USP44 expression among aneuploid cases (n = 124). P‐value was calculated using the log‐rank test.
Univariate and multivariate analyses for overall survival
| Factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| All cases ( | ||||
| Age ≥70 years (vs. <70 years) | 1.66 (1.11–2.46) | 0.0134 | 1.95 (1.28–2.95) | 0.0021 |
| Female (vs. male) | 1.18 (0.78–1.76) | 0.4220 | − | − |
| pT3,4 (vs. pT1,2) | 2.97 (1.69–5.71) | <0.0001 | 2.23 (1.18–4.54) | 0.0122 |
| pN+ (vs. pN−) | 3.26 (2.02–5.53) | <0.0001 | 2.37 (1.40–4.20) | 0.0011 |
| pM+ (vs. pM−) | 2.89 (1.91–4.32) | <0.0001 | 1.70 (1.09–2.63) | 0.0202 |
| Aneuploid (vs. diploid) | 0.97 (0.66–1.45) | 0.8896 | − | − |
| high USP44 (vs. low) | 1.51 (1.03–2.23) | 0.0354 | 1.36 (0.91–2.02) | 0.1359 |
| Diploid cases ( | ||||
| Age ≥ 70 years (vs. <70 years) | 1.44 (0.75–2.68) | 0.2685 | − | − |
| Female (vs. male) | 1.72 (0.90–3.18) | 0.0959 | 1.53 (0.79–2.86) | 0.2021 |
| pT3,4 (vs. pT1,2) | 2.72 (1.17–7.92) | 0.0172 | 1.74 (0.71–5.22) | 0.2397 |
| pN+ (vs. pN−) | 2.45 (1.27–5.12) | 0.0068 | 1.82 (0.89–3.94) | 0.1006 |
| pM+ (vs. pM−) | 3.71 (1.90–7.03) | 0.0002 | 2.54 (1.25–5.12) | 0.0108 |
| high USP44 (vs. low) | 1.01 (0.51–1.90) | 0.9750 | − | − |
| Aneuploid cases ( | ||||
| Age ≥70 years (vs. <70 years) | 1.88 (1.12–3.12) | 0.0174 | 1.99 (1.15–3.41) | 0.0141 |
| Female (vs. male) | 0.93 (0.53–1.58) | 0.7995 | − | − |
| pT3,4 (vs. pT1,2) | 3.08 (1.50–7.43) | 0.0014 | 2.00 (0.86–5.31) | 0.1128 |
| pN+ (vs. pN−) | 4.35 (2.18–9.94) | <0.0001 | 3.50 (1.59–8.63) | 0.0014 |
| pM+ (vs. pM−) | 2.60 (1.50–4.38) | 0.0009 | 1.17 (0.64–2.12) | 0.5971 |
| high USP44 (vs low) | 2.01 (1.20‐3.42) | 0.0075 | 1.83 (1.04‐3.29) | 0.0357 |
CI, confidence interval; HR, hazard ratio; USP44, ubiquitin‐specific protease 44.
Figure 3Overexpression of USP44 leads to aneuploidy. (A) USP44 mRNA expression levels in control hTERT‐RPE1 (n = 9), USP44‐1 (n = 3), USP44‐2 (n = 3), and USP44‐3 (n = 3) cell lines were measured using qRT‐PCR and standardized by β‐actin mRNA levels. *P < 0.0001. (B) Western blot analysis of USP44 protein expression in control hTERT‐RPE1 cells and the three USP44 stably overexpressing cells was performed after 30 generations. β‐actin served as loading control. (C) Representative images of chromosomes of single cell samples were shown. Diploidy (left) and aneuploidy (middle, loss; right, gain) are shown. (D) Proportion of cells with aneuploidy was determined after 30 generations in control and USP44 overexpression cells. Data are means ± SD from three independent experiments (>50 cells per experiment). (E) Individual chromosome numbers from chromosome spreads were determined (total cell number: control, n = 204; USP44, n = 223). The normal chromosome number of hTERT‐RPE1 cells is 46.